References
- Gough S. Post-marketing surveillance: a UK/European perspective. Curr Med Res Opin 2005;21:565–70
- Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care 1990;13:427–33
- UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–53
- De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JW. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005;7: 73–82